These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 7835624)

  • 1. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
    Kaakkola S; Gordin A; Männistö PT
    Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.
    Ménnistó PT
    CNS Drugs; 1994 Mar; 1(3):172-9. PubMed ID: 27520516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM; Rinne UK
    J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.
    Vieira-Coelho MA; Gomes P; Serrão MP; Soares-da-Silva P
    Kidney Int; 2001 May; 59(5):1683-94. PubMed ID: 11318939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
    Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
    Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats.
    Törnwall M; Männistö PT
    Eur J Pharmacol; 1993 Nov; 250(1):77-84. PubMed ID: 8119326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
    Li YH; Wirth T; Huotari M; Laitinen K; MacDonald E; Männistö PT
    Eur J Pharmacol; 1998 Sep; 356(2-3):127-37. PubMed ID: 9774242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.
    Lautala P; Kivimaa M; Salomies H; Elovaara E; Taskinen J
    Pharm Res; 1997 Oct; 14(10):1444-8. PubMed ID: 9358559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
    Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
    Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M; Xiao AY; Kuhn W; Lehnfeld R; Waldmeier P; Sontag KH; Riederer P
    J Neural Transm (Vienna); 2001; 108(2):189-204. PubMed ID: 11314772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
    Gerlach M; Ukai W; Ozawa H; Riederer P
    J Neural Transm (Vienna); 2002 May; 109(5-6):789-95. PubMed ID: 12111468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey.
    Günther I; Psylla M; Reddy GN; Antonini A; Vontobel P; Reist HW; Zollinger A; Nickles RJ; Beer HF; Schubiger PA
    Nucl Med Biol; 1995 Oct; 22(7):921-7. PubMed ID: 8547890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
    Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
    Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
    Forester SC; Lambert JD
    Carcinogenesis; 2014 Feb; 35(2):365-72. PubMed ID: 24148818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
    Männistö PT; Lang A; Rauhala P; Vasar E
    Eur J Pharmacol; 1995 Feb; 274(1-3):229-33. PubMed ID: 7768276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue and interspecies comparison of catechol-
    Jalkanen A; Lassheikki V; Torsti T; Gharib E; Lehtonen M; Juvonen RO
    Xenobiotica; 2021 Mar; 51(3):268-278. PubMed ID: 33289420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
    Männistö PT; Tuomainen P; Tuominen RK
    Br J Pharmacol; 1992 Mar; 105(3):569-74. PubMed ID: 1628144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.